کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3945450 1254266 2011 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: A pilot study
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی زنان، زایمان و بهداشت زنان
پیش نمایش صفحه اول مقاله
Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: A pilot study
چکیده انگلیسی

ObjectiveDetermine if pre-treatment Patient-Generated Subjective Global Assessment (PG-SGA) predicts febrile neutropenia (FN) in gynecologic cancer patients receiving primary combination chemotherapy.MethodsFollowing IRB approval, clinicopathologic variables, pre-treatment laboratory values and PG-SGA were recorded from eligible patients. Bone marrow toxicity (CTC 3.0) divided groups of patients: (1) No grade 3 or 4 neutropenia, (2) grade 3 or 4 neutropenia, (3) FN. Statistical analysis with Kruskal–Wallis one-way analysis of variance and a receiver operating characteristic (ROC) curve were performed.Results58 patients met study inclusion: 25 in group 1, 28 in group 2, and 5 in group 3. Mean age was 61 and the majority, 42 (72%), had ovarian cancer. Median PG-SGA scores were: 6 (group 1) vs. 7 (group 2) vs. 14 (group 3) (p = 0.019). Both median albumin: (1) 4.2 vs. (2) 4.0 vs. (3) 3.4 g/dl (p = 0.041), and hemoglobin: (1) 12.1 vs. (2) 11.75 vs. (3) 10.6 g/dl (p = 0.05) differed between the groups. The overall AUC of the ROC curve for PG-SGA was 0.831 ± 0.064 (95% CI = 0.706 to 0.956, p = 0.015). Using the ROC, selecting a PG-SGA score of 7.5 to be predictive of febrile neutropenia yields a sensitivity of 100% and a specificity of 60%. When the cutoff value is set at 12.5, the specificity improves to 81% while decreasing sensitivity to 80%.ConclusionsPG-SGA scores were higher for patients experiencing FN and may be a reasonably predictive marker of FN in patients receiving multi-agent primary chemotherapy and likely benefactors of prophylactic GCSF.


► PG-SGA appears to reliability predict subsequent marrow suppression and identify patients at highest risk for febrile neutropenia.
► PG-SGA may be a reasonable pre-treatment adjunct to help clinicians decide on prophylactic GCSF.
► Ideally, prospective trials may evaluate the utility of this novel approach.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Gynecologic Oncology - Volume 123, Issue 2, November 2011, Pages 360–364
نویسندگان
, , , , , ,